Investor News / RNS

Physiomics plc (AIM: PYC), the Oxford, UK based systems biology company, is pleased to announce that it has signed a contract with its first large pharma customer to supply cardiac toxicity risk modelling services. Read more...

Physiomics plc (AIM: PYC), the Oxford, UK based systems biology company, is pleased to announce that it is participating in the 2013 Safety Pharmacology Society's  annual Meeting (SPS), taking place at the Congress Centre de Doelen, Rotterdam, Netherlands, on 16-19 September 2013. Dr Hitesh Mistry will present the latest modelling advances of the cardiac toxicity predictive platform developed at Physiomics. Read more...

Physiomics plc (AIM: PYC), the Oxford, UK based systems biology company, is pleased to announce that it won the second poster prize at the NC3Rs and Society of Biology Symposium held in London on 19 June 2013. The NC3Rs is the National Centre for the Replacement, Refinement & Reduction of Animals in Research. read more ...

Physiomics is pleased to announce that it has been awarded a GBP148,465 grant from the UK’s innovation agency, the Technology Strategy Board’s Biomedical Catalyst fund. The grant will provide additional support for the development of the Company’s flagship Virtual Tumour Clinical platform. Read more....

Physiomics plc (AIM: PYC), the Oxford, UK based systems biology company, is pleased to announce that it is participating in the PAGE Meeting 2013, taking place at the Glasgow Royal Concert Hall, Glasgow,  on 11-14 June 2013. Dr Eric Fernandez, Dr Frances Brightman, and Dr Christophe Chassagnole will present on an updated version of drugCARD, on our newly release cardiac toxicity predictive platform and on our...

The current Virtual Tumour platform is a mathematical model of a growing tumour which accurately predicts the outcome of xenograft experiments. The model can also be used as a start point to design first time in human clinical regimens. Physiomics is now developing Virtual Tumour Clinical, based on the same principles as the exiting platform but using human patient data to calibrate the model. Read more....

Physiomics plc is pleased to announce that it has signed a contract with a biotechnology company to apply its new Virtual Tumour Clinical platform to their lead compound. The biotechnology company will pay an up-front technology access fee now and ongoing service fees as the project progresses. This represents the first commercial deal for Physiomics’ flagship Virtual Tumour Clinical technology. The project will commence immediately. ...

Physiomics plc (AIM: PYC), the Oxford, UK based systems biology company, is pleased to announce that it is participating in the AACR Annual Meeting 2013, taking place at the Walter E. Washington Convention Center, Washington, DC on 6-10 April 2013.  Dr Frances Brightman and Dr Eric Fernandez will present respectively on the application of the Virtual Tumour platform to radiotherapy prediction and on the latest...

Physiomics plc (AIM: PYC), the Oxford, UK-based systems biology company, is pleased to announce the launch of its new cardiac toxicity modelling service. This new model predicts the risk of a fatal heart arrhythmia known as Torsade de Pointes, using low cost and relatively easy to obtain lab-based data. From 1990 to 2010, a dozen compounds were withdrawn from the market because of association with...

The Physiomics method aims to reduce the number of candidates incorrectly rejected and also to reduce the number of compounds incorrectly advanced into costly clinical trials....